Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials
Autores da FMUP
Participantes de fora da FMUP
- Peyrin-Biroulet, Laurent
- Sands, Bruce E.
- Danese, Silvio
- Jairath, Vipul
- Goetsch, Martina
- Bhattacharjee, Abhishek
- Wu, Joseph
- Branquinho, Diogo
- Modesto, Irene
- Feagan, Brian G.
Unidades de investigação
Abstract
Abstract no disponible
Filiações
Filiações não disponíveis
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Burden of Inflammatory Bowel Disease in Portugal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico (Inflammatory Bowel) . 2023
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Magro,F,Peyrin,L,Sands,BE,Danese,S,Jairath,V,Goetsch,M,Bhattacharjee,A et al. Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials. Annual Scientific Meeting of the American-College-of-Gastroenterology (ACG). 2023. Vancouver-CANADA. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA:Springer Nature. 2023 p.p. 772-773.